Oorja Bio raised $30 million in a series A round backed by Westlake Biopartners to advance in-licensing drugs for idiopathic pulmonary fibrosis (IPF) and other fibrotic and cardiopulmonary diseases. The funding is intended to support development work that can move candidates toward later-stage clinical evaluation. The financing signals investor confidence in fibrotic disease platforms where unmet need remains high, and it complements prior venture funding waves into respiratory indications. For the sector, it adds another example of capital formation centered on translational research and productization plans rather than platform-only discovery. At the same time, the broader biotech funding calendar included multiple financing updates, but this round stands out for its direct therapeutic focus in IPF.